PL372183A1 - Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego - Google Patents
Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowegoInfo
- Publication number
- PL372183A1 PL372183A1 PL372183A PL37218305A PL372183A1 PL 372183 A1 PL372183 A1 PL 372183A1 PL 372183 A PL372183 A PL 372183A PL 37218305 A PL37218305 A PL 37218305A PL 372183 A1 PL372183 A1 PL 372183A1
- Authority
- PL
- Poland
- Prior art keywords
- anticancer drug
- glutamine
- alpha
- well
- application
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 2
- 229940041181 antineoplastic drug Drugs 0.000 title 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 abstract 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 229930195712 glutamate Natural products 0.000 abstract 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 2
- 229960003104 ornithine Drugs 0.000 abstract 2
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL372183A PL372183A1 (pl) | 2005-01-11 | 2005-01-11 | Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego |
| DE602006015608T DE602006015608D1 (de) | 2005-01-11 | 2006-01-10 | Pharmazeutische zubereitung zur verwendung in der therapie oder prophylaxe von neoplastischen erkrankungen |
| PL06700207T PL1845966T3 (pl) | 2005-01-11 | 2006-01-10 | Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych |
| CA2593780A CA2593780C (en) | 2005-01-11 | 2006-01-10 | The use of alpha-ketoglutarate in the treatment or prophylaxis of neoplastic disease |
| ES06700207T ES2349233T3 (es) | 2005-01-11 | 2006-01-10 | Preparación farmacéutica para su uso en el tratamiento o la profilaxis de enfermedades neoplásicas. |
| PCT/PL2006/000003 WO2006075924A1 (en) | 2005-01-11 | 2006-01-10 | Antineoplastic preparation and the use of antineoplastic preparation |
| JP2007550321A JP2008526838A (ja) | 2005-01-11 | 2006-01-10 | 抗新生物製剤、及び抗新生物製剤の使用 |
| AU2006205279A AU2006205279B2 (en) | 2005-01-11 | 2006-01-10 | Antineoplastic preparation and the use of antineoplastic preparation |
| US11/813,526 US7759396B2 (en) | 2005-01-11 | 2006-01-10 | Antineoplastic preparation and the use of antineoplastic preparation |
| AT06700207T ATE474570T1 (de) | 2005-01-11 | 2006-01-10 | Pharmazeutische zubereitung zur verwendung in der therapie oder prophylaxe von neoplastischen erkrankungen |
| CN2006800019675A CN101111241B (zh) | 2005-01-11 | 2006-01-10 | 抗肿瘤制备物和抗肿瘤制备物的用途 |
| EP06700207A EP1845966B1 (en) | 2005-01-11 | 2006-01-10 | Pharmaceutical preparation for use in the treatment or prophylaxis of neoplastic diseases |
| DK06700207.1T DK1845966T3 (da) | 2005-01-11 | 2006-01-10 | Farmaceutisk sammensætning til anvendelse i behandlingen eller forebyggelsen af neoplastiske sygdomme |
| US12/940,573 US20110105617A1 (en) | 2005-01-11 | 2010-11-05 | Method for treatment of neoplastic diseases with alpha-keto glutarate and/or salts thereof |
| JP2012219701A JP2013035864A (ja) | 2005-01-11 | 2012-10-01 | 抗新生物製剤、及び抗新生物製剤の使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL372183A PL372183A1 (pl) | 2005-01-11 | 2005-01-11 | Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL372183A1 true PL372183A1 (pl) | 2006-07-24 |
Family
ID=36168380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL372183A PL372183A1 (pl) | 2005-01-11 | 2005-01-11 | Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego |
| PL06700207T PL1845966T3 (pl) | 2005-01-11 | 2006-01-10 | Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06700207T PL1845966T3 (pl) | 2005-01-11 | 2006-01-10 | Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7759396B2 (pl) |
| EP (1) | EP1845966B1 (pl) |
| JP (2) | JP2008526838A (pl) |
| CN (1) | CN101111241B (pl) |
| AT (1) | ATE474570T1 (pl) |
| AU (1) | AU2006205279B2 (pl) |
| CA (1) | CA2593780C (pl) |
| DE (1) | DE602006015608D1 (pl) |
| DK (1) | DK1845966T3 (pl) |
| ES (1) | ES2349233T3 (pl) |
| PL (2) | PL372183A1 (pl) |
| WO (1) | WO2006075924A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2033623A1 (en) | 2007-09-07 | 2009-03-11 | Cutech S.R.L. | Compositions comprising ornithine ketoglutarate (OKG) |
| US20160354334A1 (en) * | 2014-02-12 | 2016-12-08 | The Regents Of The University Of California | Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT393221B (de) * | 1988-02-03 | 1991-09-10 | Leopold Pharma Gmbh | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken |
| FR2775901B1 (fr) * | 1998-03-13 | 2000-07-21 | Logeais Labor Jacques | Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments |
| SE0201713D0 (sv) * | 2001-11-23 | 2002-06-06 | Gramineer Internat Ab | New methods and use III |
| MXPA05001267A (es) | 2002-08-01 | 2005-10-18 | Aesgen Inc | Tratamiento mejorado de cancer con glutamina. |
| AT412447B (de) * | 2002-11-27 | 2005-03-25 | C Y L Handelsges M B H | Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung |
| EP1534305B9 (en) * | 2003-05-07 | 2007-03-07 | Osteologix A/S | Treating cartilage / bone conditions with water-soluble strontium salts |
| US20050124684A1 (en) * | 2003-08-29 | 2005-06-09 | Ying Du | 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production |
| DK1824470T3 (da) | 2004-12-17 | 2014-08-18 | Cash Alan Brian | Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom |
-
2005
- 2005-01-11 PL PL372183A patent/PL372183A1/pl not_active Application Discontinuation
-
2006
- 2006-01-10 DK DK06700207.1T patent/DK1845966T3/da active
- 2006-01-10 AU AU2006205279A patent/AU2006205279B2/en not_active Ceased
- 2006-01-10 US US11/813,526 patent/US7759396B2/en not_active Expired - Fee Related
- 2006-01-10 CA CA2593780A patent/CA2593780C/en not_active Expired - Fee Related
- 2006-01-10 PL PL06700207T patent/PL1845966T3/pl unknown
- 2006-01-10 ES ES06700207T patent/ES2349233T3/es active Active
- 2006-01-10 WO PCT/PL2006/000003 patent/WO2006075924A1/en not_active Ceased
- 2006-01-10 EP EP06700207A patent/EP1845966B1/en not_active Not-in-force
- 2006-01-10 AT AT06700207T patent/ATE474570T1/de not_active IP Right Cessation
- 2006-01-10 JP JP2007550321A patent/JP2008526838A/ja not_active Ceased
- 2006-01-10 DE DE602006015608T patent/DE602006015608D1/de active Active
- 2006-01-10 CN CN2006800019675A patent/CN101111241B/zh not_active Expired - Fee Related
-
2012
- 2012-10-01 JP JP2012219701A patent/JP2013035864A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006075924A1 (en) | 2006-07-20 |
| EP1845966B1 (en) | 2010-07-21 |
| US7759396B2 (en) | 2010-07-20 |
| DE602006015608D1 (de) | 2010-09-02 |
| CN101111241B (zh) | 2010-12-01 |
| US20080058422A1 (en) | 2008-03-06 |
| JP2013035864A (ja) | 2013-02-21 |
| PL1845966T3 (pl) | 2011-02-28 |
| EP1845966A1 (en) | 2007-10-24 |
| ES2349233T3 (es) | 2010-12-29 |
| CA2593780A1 (en) | 2006-07-20 |
| AU2006205279B2 (en) | 2011-05-26 |
| AU2006205279A1 (en) | 2006-07-20 |
| CA2593780C (en) | 2013-11-26 |
| ATE474570T1 (de) | 2010-08-15 |
| CN101111241A (zh) | 2008-01-23 |
| DK1845966T3 (da) | 2010-11-08 |
| JP2008526838A (ja) | 2008-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2584043A3 (en) | Anti-glypican 3 antibody having improved kinetics in plasma | |
| TNSN07452A1 (en) | Stabile active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine | |
| MY148960A (en) | The use of phosphoketolase for producing useful metabolites | |
| CA2496623A1 (en) | Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives | |
| MX2009006865A (es) | Proceso para la preparacion de compuestos 6,6-dimetil-3-aza-bicicl o-[3.1.0]-hexano utilizando intermediario bisulfitico. | |
| IL185031A0 (en) | Method for the preparation of pregabalin and salts thereof | |
| GB0401088D0 (en) | Phosphoramidate derivatives | |
| WO2008053297A3 (en) | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa | |
| WO2008099874A1 (ja) | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 | |
| EP3249405A3 (en) | Stabilizing composition for immobilized biomolecules | |
| ZA201005615B (en) | Pharmaceutical compositions of entacapone,levodopa and carbidopa with improved bioavailability | |
| MX2010000942A (es) | Composicion. | |
| UA89904C2 (ru) | β КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ | |
| SG170796A1 (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors | |
| WO2007016352A3 (en) | Oral liquid losartan compositions | |
| WO2006062424A3 (en) | Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system | |
| TNSN07228A1 (en) | Manufacture process of organic compounds | |
| PL372183A1 (pl) | Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego | |
| PL1750703T3 (pl) | Sposób obniżania toksyczności żołądkowo-jelitowej powodowanej podawaniem tegafuru | |
| ZA200800138B (en) | Process for the preparation of crystalline perindopril | |
| EP2151499A3 (en) | Processes for the preparation of phosphatides | |
| WO2007132478A3 (en) | Process for the preparation of pure risedronic acid or salts | |
| IL205083A0 (en) | Process for the preparation of tetranorlabdane derivatives | |
| WO2009000909A8 (en) | Salts of perindopril | |
| WO2007087056A3 (en) | Peramivir derivative for oral administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |